{"id":334671,"date":"2017-03-01T22:04:09","date_gmt":"2017-03-01T14:04:09","guid":{"rendered":"http:\/\/techcrunch.com\/?p=1458926"},"modified":"2017-03-01T22:04:09","modified_gmt":"2017-03-01T14:04:09","slug":"in-liquid-biopsy-race-freenome-lands-65-million-led-by-andreessen-horowitz","status":"publish","type":"post","link":"https:\/\/people.utm.my\/asmawisham\/in-liquid-biopsy-race-freenome-lands-65-million-led-by-andreessen-horowitz\/","title":{"rendered":"In liquid biopsy race, Freenome lands $65 million, led by Andreessen Horowitz"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/tctechcrunch2011.files.wordpress.com\/2017\/03\/screen-shot-2017-02-28-at-10-35-31-pm.png?w=738\" class=\"\"\/><\/p>\n<p><a target=\"_blank\" href=\"https:\/\/www.freenome.com\/\">Freenome<\/a>, a two-year-old liquid biopsy diagnosis platform that detects the cell-free DNA sequencing of cancer, has raised a huge Series A round \u2014 $65 million\u00a0\u2014 led by Andreessen Horowitz, <a target=\"_blank\" href=\"https:\/\/techcrunch.com\/2016\/06\/09\/liquid-biopsy-startup-freenome-lands-5-5-million-led-by-andreessen-horowitz\/\">which also<\/a> led the company\u2019s $5.5 million seed round less than a year ago.<\/p>\n<p>Other investors in the deal include\u00a0GV, Polaris Partners, Innovation Endeavors, Spectrum 28, Asset Management Ventures, Charles River Ventures, AME Cloud Ventures, Allen and Company and earlier backers Data Collective and Founders Fund.<\/p>\n<p>The amount of money involved speaks to the opportunity \u2014 as well as the competition \u2014 that Freenome is facing. A glut of liquid biopsy companies have emerged\u00a0from universities and elsewhere in recent years to catch cancer by relying on a patient\u2019s DNA, rather than having to extract\u00a0their tissue. What these medical test companies haven\u2019t been able to pinpoint exactly is where a cancer is growing, how serious a threat it is, and whether it will respond to treatment.<\/p>\n<p>That\u2019s not for lack of trying\u00a0\u2014 or funding.<\/p>\n<p>Guardant Health, a four-year-old, Redwood Shores, Ca.-based company whose non-invasive genomic sequencing test for cancer requires just two vials of blood, has raised so far raised <a target=\"_blank\" href=\"https:\/\/techcrunch.com\/2016\/01\/07\/guardant-health-which-tests-for-cancer-through-blood-samples-raises-nearly-100-million-more\/\">$190 million<\/a>, including from OribMed Advisors, Khosla Ventures, and Sequoia Capital.<\/p>\n<p>Grail, a four-year-old, Venice, Ca.-based early cancer screening startup\u00a0that spun out of the DNA-sequencing giant Illumina is reportedly looking to raise up to <a target=\"_blank\" href=\"https:\/\/news.fastcompany.com\/illumina-spinout-grail-is-seeking-to-raise-17-billion-for-large-scale-clinical-trial-sources-4026271\">$1.7 billion<\/a> in fresh funding to launch a large-scale clinical trial. ( In January of last year, it separately raised $100 million in Series A funding from Illumia,\u00a0Microsoft cofounder Bill Gates, Amazon founder Jeff Bezos, and GV.)<\/p>\n<p>Freenome cofounder and CEO Gabe Otte told us last year that the\u00a0\u201cbig differentiator here is that our technology allows us to answer [more questions than do competitors]\u00a0because we\u2019re looking at different biologies. \u00a0. \u00a0.We wanted to answer not just cancer or not cancer, but malignant or benign, and where the tissue is. So we capture all the [genetic material floating in our blood] rather than fixating on a few mutations known to be associated with cancer.\u201d<\/p>\n<p>At the time, Otte also said Freenome had validated its tests with hundreds of samples but it wasn\u2019t ready to\u00a0\u201cblow $100 million\u201d in venture capital on its platform before its technology is proven beyond a doubt.<\/p>\n<p>Apparently, Freenome is feeling better about its odds today. Indeed, the 25-person company has now tested thousands of blood samples, and it says its tests\u00a0outperform current screening tests on the market for\u00a0four types of cancer: prostate, breast, colorectal, and lung.<\/p>\n<p>Now Freenome is\u00a0using its massive round to expand\u00a0into clinical trails, including with the help of 25 research partners that include the\u00a0University of California San Diego and UCSF. The idea, says Otte, is to answer relevant questions about each cancer.<\/p>\n<p>With lung cancer, for example, it wants to be able to resolve whether a test shows non-small-cell lung carcinoma or small cell lung carcinoma. (The first is far less responsive to chemotherapy.) Otte says a machine learning component that \u201ccan create a screening test in software and learn from its mistakes and and answer not just a single question but multiple questions,\u201d should help.<\/p>\n<p>If all goes well, suggests\u00a0Otte, Freenome will have tested as many as 10,000 blood samples both in its own lab as well as via the various groups doing sequencing on its behalf within the next 12 months. After that, it\u00a0can potentially move on to talks with the appropriate regulatory bodies for approval.<\/p>\n<p>Then, the thinking goes, it\u2019s into the doctor\u2019s office, as long as it can get there first.<\/p>\n","protected":false},"excerpt":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" width=\"680\" height=\"565\" src=\"https:\/\/tctechcrunch2011.files.wordpress.com\/2017\/03\/screen-shot-2017-02-28-at-10-35-31-pm.png?w=680\" class=\"attachment-large size-large wp-post-image\" alt=\"screen-shot-2017-02-28-at-10-35-31-pm\" srcset=\"https:\/\/tctechcrunch2011.files.wordpress.com\/2017\/03\/screen-shot-2017-02-28-at-10-35-31-pm.png?w=680 680w, https:\/\/tctechcrunch2011.files.wordpress.com\/2017\/03\/screen-shot-2017-02-28-at-10-35-31-pm.png?w=150 150w, https:\/\/tctechcrunch2011.files.wordpress.com\/2017\/03\/screen-shot-2017-02-28-at-10-35-31-pm.png?w=300 300w, https:\/\/tctechcrunch2011.files.wordpress.com\/2017\/03\/screen-shot-2017-02-28-at-10-35-31-pm.png?w=768 768w, https:\/\/tctechcrunch2011.files.wordpress.com\/2017\/03\/screen-shot-2017-02-28-at-10-35-31-pm.png 958w\" sizes=\"(max-width: 680px) 100vw, 680px\" \/>&nbsp;Freenome, a two-year-old liquid biopsy diagnosis platform that detects the cell-free DNA sequencing of cancer, has raised a huge Series A round &#8212; $65 million\u00a0&#8212; led by Andreessen Horowitz, which also led the company&#8217;s $5.5 million seed round less than a year ago.<br \/>\nOther investors in the deal include\u00a0GV, Polaris Partners, Innovation Endeavors, Spectrum 28, Asset Management&#8230; <a href=\"https:\/\/techcrunch.com\/2017\/03\/01\/in-liquid-biopsy-race-freenome-lands-65-million-led-by-andreessen-horowitz\/?ncid=rss\">Read More<\/a><\/p>\n<div class=\"feedflare\">\n<a href=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?a=9VKqn4pDO4Q:TDRckqzhZTE:2mJPEYqXBVI\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?d=2mJPEYqXBVI\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?a=9VKqn4pDO4Q:TDRckqzhZTE:7Q72WNTAKBA\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?d=7Q72WNTAKBA\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?a=9VKqn4pDO4Q:TDRckqzhZTE:yIl2AUoC8zA\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?d=yIl2AUoC8zA\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?a=9VKqn4pDO4Q:TDRckqzhZTE:-BTjWOF_DHI\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?i=9VKqn4pDO4Q:TDRckqzhZTE:-BTjWOF_DHI\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?a=9VKqn4pDO4Q:TDRckqzhZTE:D7DqB2pKExk\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?i=9VKqn4pDO4Q:TDRckqzhZTE:D7DqB2pKExk\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?a=9VKqn4pDO4Q:TDRckqzhZTE:qj6IDK7rITs\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?d=qj6IDK7rITs\" border=\"0\"><\/img><\/a>\n<\/div>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Techcrunch\/~4\/9VKqn4pDO4Q\" height=\"1\" width=\"1\" alt=\"\"\/> <\/p>\n","protected":false},"author":5817,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[25],"tags":[59,66,26],"class_list":["post-334671","post","type-post","status-publish","format-standard","hentry","category-technology","tag-media","tag-techcrunch","tag-technology"],"_links":{"self":[{"href":"https:\/\/people.utm.my\/asmawisham\/wp-json\/wp\/v2\/posts\/334671","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/people.utm.my\/asmawisham\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/people.utm.my\/asmawisham\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/people.utm.my\/asmawisham\/wp-json\/wp\/v2\/users\/5817"}],"replies":[{"embeddable":true,"href":"https:\/\/people.utm.my\/asmawisham\/wp-json\/wp\/v2\/comments?post=334671"}],"version-history":[{"count":0,"href":"https:\/\/people.utm.my\/asmawisham\/wp-json\/wp\/v2\/posts\/334671\/revisions"}],"wp:attachment":[{"href":"https:\/\/people.utm.my\/asmawisham\/wp-json\/wp\/v2\/media?parent=334671"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/people.utm.my\/asmawisham\/wp-json\/wp\/v2\/categories?post=334671"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/people.utm.my\/asmawisham\/wp-json\/wp\/v2\/tags?post=334671"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}